8-K: Arcturus Therapeutics Reports Q4 and Fiscal Year 2023 Results, Highlights Pipeline Progress and Extended Cash Runway

Arcturus Therapeutics announced its fourth quarter and full year 2023 financial results, along with key pipeline advancements, including the anticipated launch of Kostaive in Japan and extended cash runway to Q1 2027.

Summary

• Arcturus Therapeutics reported a revenue of $169.9 million for the year ended December 31, 2023, compared to $206.0 million in 2022, with a significant portion coming from the CSL collaboration.
• The company's operating expenses for 2023 totaled $245.0 million, up from $193.8 million in 2022, driven by increased research and development activities.
• Arcturus experienced a net loss of $26.6 million for the year, compared to a net income of $9.3 million in the previous year.
• For the fourth quarter of 2023, revenue was $34.0 million, a decrease from $160.3 million in the same period of 2022, which was largely due to a $200 million upfront payment from CSL in 2022.
• The company's cash, cash equivalents, and restricted cash stood at $348.9 million as of December 31, 2023, compared to $394.0 million at the end of 2022.
• Arcturus has extended its cash runway to the first quarter of 2027, primarily due to disciplined cost management and the CSL collaboration.
• The company anticipates the launch of Kostaive in Japan this year and expects interim data from ARCT-032 Phase 1b and ARCT-810 Phase 2 studies in Q2 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments such as the Kostaive approval, extended cash runway, and pipeline progress, the company also reported a net loss and decreased revenue. The sentiment is cautiously optimistic due to the potential of their technology and pipeline, but tempered by the financial results.

Positives

• The company has successfully extended its cash runway to Q1 2027, providing financial stability.
• Kostaive's approval and anticipated launch in Japan mark a significant commercial milestone.
• The Orphan Drug Designations for ARCT-032 from both the U.S. FDA and European Commission will help advance its development.
• Clinical data shows Kostaive has a superior immune response compared to a conventional mRNA vaccine.
• The company has initiated new vaccine discovery programs for Lyme Disease and Gonorrhea, expanding its pipeline.
• The company has received approximately $396 million in upfront payments and milestones from CSL as of December 31, 2023.

Negatives

• The company reported a net loss of $26.6 million for the year ended December 31, 2023, compared to a net income of $9.3 million in 2022.
• Revenue decreased to $169.9 million in 2023 from $206.0 million in 2022, primarily due to the discontinuation of collaboration agreements with Vinbiocare and Janssen.
• Operating expenses increased to $245.0 million in 2023 from $193.8 million in 2022.
• The fourth quarter revenue decreased significantly from $160.3 million in 2022 to $34.0 million in 2023.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The success of the company's pipeline, including ARCT-032 and ARCT-810, is not guaranteed.
• Clinical data may not be predictive of future clinical results.
• The company's ability to enroll participants in clinical studies is subject to risks.
• The timing of commercial activities for the LUNAR-COVID program is uncertain.
• The likelihood of patent issuance from any patent application is not guaranteed.
• The collection of accounts receivables, including expected payments from CSL, is subject to risks.
• The company's cash burn and runway are subject to change.
• General business and economic conditions could impact the company's performance.

Future Outlook

Arcturus anticipates the launch of Kostaive in Japan this year and expects interim data from ARCT-032 Phase 1b and ARCT-810 Phase 2 studies in Q2 2024. The company also expects to continue to receive future milestone payments from CSL.

Management Comments

• Joseph Payne, President & CEO of Arcturus Therapeutics, stated he is excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023.
• Mr. Payne noted that Kostaive was granted historic approval as the world's first self-amplifying mRNA product.
• Mr. Payne also mentioned that the U.S. FDA and the European Commission recently granted Orphan Drug Designation for ARCT-032.
• Andy Sassine, Chief Financial Officer of Arcturus, stated he is pleased to announce the cash runway was extended to the first quarter 2027 due to disciplined cost management and progression of the CSL collaboration.

Industry Context

This announcement highlights Arcturus's progress in the mRNA therapeutics and vaccine space, particularly with the approval of Kostaive, which positions them as a leader in self-amplifying mRNA technology. The company's focus on rare diseases and infectious diseases aligns with current industry trends in personalized medicine and pandemic preparedness. The collaboration with CSL Seqirus is a key factor in their commercialization strategy.

Comparison to Industry Standards

• Arcturus's Kostaive is the first approved self-amplifying mRNA vaccine, setting it apart from competitors like Moderna and BioNTech, which use conventional mRNA technology.
• The superior immune response of Kostaive with a lower dose compared to Comirnaty (Pfizer/BioNTech) demonstrates a potential advantage in efficacy and cost-effectiveness.
• The Orphan Drug Designations for ARCT-032 are similar to other companies developing treatments for rare diseases, such as Vertex Pharmaceuticals in cystic fibrosis.
• The extended cash runway to Q1 2027 provides Arcturus with a longer period of financial stability compared to some smaller biotech companies that often face near-term funding challenges.
• The collaboration with CSL Seqirus is similar to other partnerships in the pharmaceutical industry, such as the collaboration between BioNTech and Pfizer, but with a focus on self-amplifying mRNA technology.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the extended cash runway and pipeline progress.
• Employees may be positively impacted by the company's continued growth and development.
• Patients with cystic fibrosis and ornithine transcarbamylase deficiency may benefit from the development of ARCT-032 and ARCT-810.
• CSL Seqirus, as a partner, will benefit from the continued collaboration and development of mRNA vaccines.
• Customers in Japan will have access to the newly approved Kostaive vaccine.

Next Steps

• The company anticipates the launch of Kostaive in Japan this year.
• Interim data from ARCT-032 Phase 1b study is expected in Q2 2024.
• Interim data from ARCT-810 Phase 2 study is expected by the end of Q2 2024.
• The company will continue to advance its vaccine discovery programs for Lyme Disease and Gonorrhea.
• The company will continue to advance the development of ARCT-810, an mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.
• The company will continue to advance the development of ARCT-032, an inhaled mRNA therapeutic candidate for individuals with cystic fibrosis.

Key Dates

Keywords

mRNA, vaccine, therapeutics, Kostaive, ARCT-032, ARCT-810, CSL Seqirus, LUNAR, STARR, Orphan Drug Designation, COVID-19, influenza, cystic fibrosis, ornithine transcarbamylase deficiency, Lyme Disease, Gonorrhea